A2K

Syndicate content

13 May 2014: WHO Technical Consultation on Innovative Models for New Antibiotics’ Development and Preservation

Knowledge Ecology International - Wed, 27/08/2014 - 09:32

In a concerted bid to contain the emerging threat posed by antibiotic resistance, in May 2014, the World Health Organization's (WHO) 67th World Health Assembly (WHA) passed WHA resolution 67.25 on "Antimicrobial resistance" instructing the WHO to "develop a global action plan to combat antimicrobial resistance" by May 2015 (Source: WHO page on Draft Global action plan on antimicrobial resistance).

read more

Categories: Front page

TDR and the Pooled Fund for R&D: WHO demonstration projects and CEWG follow-up

Knowledge Ecology International - Mon, 18/08/2014 - 14:09

In May 2014, the World Health Organization's (WHO) 67th World Health Assembly (WHA67) passed decision WHA67(15) setting the stage for the creation of a new pooled funding mechanism for R&D.

read more

Categories: Front page

OMB's Revised Guidance on Appointment of Lobbyists to Federal Advisory Committees, Boards, and Commissions

Knowledge Ecology International - Fri, 15/08/2014 - 14:58

Following litigation by several lobbyists, OMB is revising its guidance on the appointment of lobbyists to federal advisory committees, boards, and commissions. Now, lobbyists can serve on these committees, including the USTR advisory boards. Money quote:

read more

Categories: Front page

Gilead's US patient access programs for Sovaldi

Knowledge Ecology International - Sat, 09/08/2014 - 15:21

This is a note on Gilead run or funded programs that are available for patients residing in the United States.

Recently, Gilead's new hepatitis C drug, Sovaldi, has received much attention and criticism for its high price of $1000 a day.

read more

Categories: Front page

Some recent cancer drug prices

Knowledge Ecology International - Wed, 06/08/2014 - 01:01

Attached are two annexes from our 2014 USTR Special 301 comments

Categories: Front page

January 2013: Proposal for the inclusion of trastuzumab in WHO EML for treatment of HER2-Positive Breast Cancer

Knowledge Ecology International - Tue, 05/08/2014 - 17:47

On 14 January 2013, Knowledge Ecology International (KEI), the University of California (San Francisco), Universities Allied for Essential Medicines (UAEM), and the Third World Network (TWN) submitted a Proposal for the Inclusion of Trastuzumab in the WHO Model List of Essential Medicines for the Treatment of HER2-Positive Breast Cancer to WHO's Expert Committee on the Selection and Use of Essentia

read more

Categories: Front page

Money speaks: USTR releases letters from Congress backing PhRMA on exclusive rights biologic test data in TPP

Knowledge Ecology International - Mon, 04/08/2014 - 19:29

As part of a partial response to FOIA request, USTR has provided KEI with copies of 13 letters sent by members of Congress, from July 27, 2011 to August 8, 2013, on the topic of biologic drug test data provisions in the TPP negotiation. We had obtained several but not all of these letters earlier from a variety of sources, including from PhRMA's web page -- where some had been proudly displayed. (See link below).

Were there letters on the other side? Yes, three. (see below).

With the FOIA request, we have also obtained the responses to the letters.

read more

Categories: Front page

Gilead's MPP license for tenofovir alafenamide (TAF) patents

Knowledge Ecology International - Fri, 01/08/2014 - 12:10

On July 24, 2014, the Medicines Patent Pool announced welcome modifications and expansions of their licensing agreement with Gilead. Among the significant changes were the addition of a new drug, tenofovir alafenamide (TAF), formerly known as GS-7340. TAF is a nucleotide reverse transcriptase inhibitor, and a prodrug of tenofovir. TAF is considered to have similar antiretroviral efficacy to tenofovir disoproxil fumarate (TDF), the drug it may replace in use, but can be administered with smaller doses and with less adverse effect on kidneys and bones.

read more

Categories: Front page

Hepatitis research and development timeline

Knowledge Ecology International - Mon, 28/07/2014 - 18:15

KEI is creating a timeline for various events relating to the discovery and the development of diagnostics, vaccines and drugs for Hepatitis. A working draft of the timeline is available here.

Categories: Front page

WIPO General Assembly 2014: Hard Decisions on the Design Law Treaty and Treaty for Protection of Genetic Resources

Knowledge Ecology International - Thu, 24/07/2014 - 15:24

The Assemblies of the Member States of the World Intellectual Property Organization (WIPO) convenes its Fifty-Fourth Series of meetings in Geneva from 22 September 2014 to 30 September 2014. These Assemblies include, inter alia, meetings of the WIPO General Assembly, the WIPO Coordination Committee, the Paris Union Assembly, the Berne Union Assembly, the Madrid Union Assembly, the Lisbon Union Assembly, the Patent Cooperation Treaty Assembly, the WIPO Copyright Treaty (WCT) Assembly and the WIPO Performances and Phonograms Treaty (WPPT) Assembly.

read more

Categories: Front page

Hepatitis C Virus patent assignments: patents with HCV in the patent claim

Knowledge Ecology International - Tue, 22/07/2014 - 14:35

To get a quick look at who is holding patents on the Hepatitis C Virus, I did some searches of the USPTO database. In each search, I looked for the term HCV in the field for patent claims (ACLM). Note this is fairly arbitrary, and I get different (and higher) numbers if I include HCV in the Abstract. In any case:

There were 1164 patents that have the term HCV in the patent claim.

read more

Categories: Front page

KEI Policy Brief: Non-Voluntary use of HCV patents in the United States

Knowledge Ecology International - Fri, 18/07/2014 - 12:43

Attached is policy briefing note that sets out possible mechanisms to overcome the exclusive rights of patents for drugs to treat the Hepatitis C Virus (HCV), in the United States. Each approach involves leadership from different actors. Each has advantages and disadvantages, including legal and practical risks. (Available here)

Table of Contents
1. The Federal Government use of HCV patents, without permission from right holder

read more

Categories: Front page

SCCR28: Chair’s Conclusions (No recommendations on broadcasting or limitations and exceptions for libraries and archives)

Knowledge Ecology International - Fri, 18/07/2014 - 10:42

At 12:50 AM on 5 July 2014, the World Intellectual Property Organization's (WIPO) 28th Standing Committee on Copyright and Related Rights concluded without reaching agreement on recommendations to the WIPO General Assembly on the following two topics: 1) Protection of Broadcasting Organizations and 2) Limitations and exceptions: libraries and archives.

read more

Categories: Front page

Gilead in 2013: AbbVie sought to eliminate competition and dominate market for HCV drugs

Knowledge Ecology International - Wed, 16/07/2014 - 18:34

I had not seen this lawsuit filed by Gilead against AbbVie and Abbott before. It is an interesting read. According to Gilead:

Abbott executives and “inventors” conspired and carried out the initial steps of the company’s scheme by filing serial fraudulent patent applications asserting that Abbott had invented methods of treating HCV using PSI-7977 as well as the Gilead Combination (as well as thousands of combinations of Abbott’s other competitors’ HCV compounds). The first of these applications is dated October 21, 2011.

read more

Categories: Front page

KEI asks FTC to investigate Shire decision to abandon efforts to compete in US market for Fabry’s disease treatments

Knowledge Ecology International - Tue, 15/07/2014 - 11:43

July 15, 2014

Knowledge Ecology International (KEI) asks the FTC to investigate Shire decision to abandon efforts to compete in US market for Fabry’s disease treatments. Letter to FTC provides evidence of possible conspiracy to segment markets, involving licensing of an NIH funded invention for use in Europe, in return for abandoning efforts to enter US market.

For More Information:

James Love, Knowledge Ecology International
Email: james.love@keionline.org
Tel +1.202.332.2670
Cell +1.202.361.3040

read more

Categories: Front page

New UK Parliamentary report on Global TB urges the United Kingdom to explore a WTO Agreement on the Provision of Public Goods

Knowledge Ecology International - Mon, 14/07/2014 - 11:32

On 8 July 2014, the United Kingdom of Great Britain and Northern Ireland's All-Party Parliamentary Group on Global Tuberculosis (APPGTB) released a seminal report entitled, "Dying for a Cure: Research and Development for Global Health." The APPGTB is co-chaired by Andrew George MP (St Ives, Liberal Democrat), Rt Hon Nick Herbert MP (Arundel and South Downs, Conservative) and Virendra Sharma MP (Ealing Southall,

read more

Categories: Front page

US Court issues compulsory license for know-how protected as trade secret

Knowledge Ecology International - Sat, 12/07/2014 - 11:14

In "Compulsory License as a Remedy for Trade Secret Misappropriation, Dennis Crouch writes* about a July 1, 2014 decision in Sabatino Bianco, M.D. v. Globus Medical, 2:12-cv-00147 (E.D. Tex 2014). The decision by Judge Bryson, a U.S. Circuit Judge in the Eastern District of Texas, concerns trade secrets which:

"consisted of ideas for the design of a medical device known as an adjustable intervertebral spacer or implant. Intervertebral spacers are used in spinal surgery to replace damaged discs in patients’ spines."

read more

Categories: Front page

Senators Wyden and Grassley launch investigation of pricing of Sovaldi, treatment for Hepatitis C Virus

Knowledge Ecology International - Fri, 11/07/2014 - 16:42

Senators Wyden and Grassley have written a very tough request for documents about the pricing of Sovaldi, sent to John C. Martin, the Chair and CEO of Gilead Sciences.

The eight page letter sets out in 21 number paragraphs and countless sub-paragraphs a set requests for documents and information related to a very sweeping number of issues relating to Hepatitis C, and the pricing of Sovaldi (Gilead's brand name for sofosbuvir).

The Grassley press release on the letter is here:

read more

Categories: Front page

28 October 2014: WTO Innovation Fair on the margins of WTO TRIPS Council review of the Paragraph 6 system

Knowledge Ecology International - Fri, 11/07/2014 - 14:56

On 28 October 2014, the World Trade Organization (WTO) will host the inaugural WTO Innovation Fair which will "feature a diverse array of creators and inventors including individuals and organizations from around the globe and will serve as a platform for exchange of information, introduction of new technologies and advancing the understanding of the innovation lifecycle – from research and development, to financing and commercialization." (Source: Website of the Permanent Mission

read more

Categories: Front page

IGC28: African Group Statement on Convening a Diplomatic Conference for the Protection of Genetic Resources, TK and folklore

Knowledge Ecology International - Thu, 10/07/2014 - 09:24

On 9 July 2014, Kenya, on behalf of the African Group, delivered the following closing statement articulating its view that substantial progress had been made in text-based negotiations on genetic resources, traditional knowledge and folklore for the WIPO General Assembly in September 2014 to take a decision to convene a Diplomatic Conference in November 2015.

read more

Categories: Front page